• Vaccine Name: rLSDV-Rabies-gP
• Target Pathogen: Rabies virus
• Target Disease: Rabies
• Vaccine Ontology ID: VO_0004762
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Glycoprotein G gene engineering:
  • Type: Recombinant vector construction
  • Description: Recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) (Aspden et al., 2003).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001111
• Preparation: Using the rabies virus glycoprotein (RG) as a model antigen, the recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) was able to express RG (Aspden et al., 2003).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: NMRI mice (3–4 weeks, n=30 per group; South African Vaccine Producers) were inoculated intramuscularly on days 0 and 14 with either PBS (50 μl), rLSDV-RG (5×10^4 f.f.u. ml−1 in 50 μl), LSDV-wt (5×10^4 f.f.u. ml−1 in 50 μl) or Verorab (1/10 human equivalent dose in 50 μl) (Aspden et al., 2003).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: On day 21, ten mice from each group were challenged intracranially with 8×10^−1 LD50, 8×10^−2 LD50 or 8×10^−3 LD50 dilution of live rabies virus (Aspden et al., 2003).
• Efficacy: Mice immunized with rLSDV-RG elicited levels of RV-specific cellular immunity (T-cell proliferation) comparable with those of mice immunized with a commercial inactivated rabies vaccine (Verorab; Pasteur Merieux). Most importantly, mice immunized with rLSDV-RG were protected from an aggressive intracranial rabies virus challenge (Aspden et al., 2003).